Alprenolol


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO HTN 200 mg/day in divided doses, may increase wkly if needed. Angina pectoris; Cardiac arrhythmias 200-400 mg/day in divided doses.
Dosage Details
Oral
Hypertension
Adult: 200 mg/day in divided doses, increased wkly according to patient response.

Oral
Angina pectoris, Cardiac arrhythmias
Adult: 200-400 mg/day in divided doses.
Contraindications
2nd and 3rd degree AV block; sinus bradycardia; uncontrolled heart failure; asthma or bronchospasm, severe peripheral arterial disease, metabolic acidosis, phaeochromocytoma. Concomitant use w/ clonidine.
Special Precautions
1st degree AV block. May mask symptoms of hyperthyroidism and hypoglycaemia. May unmask myasthenia gravis. May aggravate psoriasis. Abrupt withdrawal may cause angina, MI, ventricular arrhythmias and death. Patients on long-term treatment should discontinue medication gradually over 1-2 wk. Pregnancy and lactation.
Adverse Reactions
Bradycardia; heart failure, heart block; hypotension; bronchospasm; fatigue; coldness of extremities; pneumonitis; pulmonary and retroperitoneal fibrosis; pleurisy; CNS effects; myopathies; GI disturbances; reversible alopoecia; skin rash; pruritus; lupus-like syndrome; male impotence; sclerosing peritonitis; muscle cramps; paraesthesias; peripheral neuropathy; haematological reactions. Changes in blood concentrations of glucose, triglycerides and cholesterol.
Drug Interactions
Concomitant use w/ other drugs that cause hypotension; NSAIDs; other cardiac depressants; sotalol; digoxin; insulin and oral hypoglycaemics; sympathomimetics; ACE inhibitors; Ca-channel blockers, verapamil. Anaesthetics causing myocardial depression (e.g. ether, cyclopropane, trichloroethylene).
Potentially Fatal: Increased risk of withdrawal HTN w/ clonidine. Withdraw several days before slowly discontinuing clonidine.
Action
Description: Alprenol is a non-cardioselective β-blocker w/ intrinsic sympathomimetic activity and some membrane-stabilising properties.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Alprenolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in